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 Long Hauler Covid-19 is a condition that describes a person who has 
recovered from Covid-19 and is declared with a negative PCR smear 2 times 
but still feels signs and symptoms for a longer period of time, even severe 
and critical symptoms. Most cases complicate Acute Respiratory Disorder 
Syndrome (ARDS), which can lead to death. Fulfilment of non-invasive high 
concentration oxygenation requirements as an intervention modality in this 
case. The purpose of this case study was to determine the effect of giving 
oxygen therapy through the High Flow Nasal Cannula (HFNC) on the 
respiratory function of Covid-19 long haulier patients. The method of 
nursing care was a case study on 2 respondents with a descriptive approach 
method. There were 2 cases of Long haulier Covid-19 patients with 
comorbid smokers, Diabetes Mellitus, experiencing moderate ARDS 
complications, desaturation, and tachypnea. Patients received oxygen 
therapy intervention through HFNC while being treated in the critical care 
room, and after being given HFNC oxygen therapy for 5 days there was a 
decrease in respiratory frequency, a change in breathing pattern from 
shortness of breath to shortness of breath, an increase in oxygen saturation, 
an increase in the ROX Index, an increase in PO2 and blood pH in normal 
limit. Nursing care that focuses on respiratory management in covid-19 long 
haulier patients improves patient outcomes in particular, namely decreased 
respiratory rate, changes in the respiratory pattern of shortness of breath, 
increased oxygen saturation, increased ROX index, increased PO2 and blood 
pH within normal limits. 
 
INTRODUCTION  
Long hauler Covid-19 is a term that 
describes the phenomenon of symptoms 
experienced by patients after being infected 
with COVID-19.1 Someone who has 
recovered from Covid-19 and tested 
negative but still feels signs and symptoms 
for longer.2 The symptoms felt by sufferers 
of Covid-19 vary. About 80% of people with 
Covid-19 experience mild symptoms and 
can recover in just two weeks. However, 
there are also those who experience a 
severe response that takes three to six 
weeks. A person is said to have a Covid-19 
long hauler if he is infected with the corona 
virus and experiences symptoms for 28 
days or more after being infected. A 
research and survey published in August 
2020 showed that 50-80% of sufferers still 
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experience disturbing symptoms within 3 
months of recovering from COVID-19.3 
Health workers and researchers have 
focused on the acute phase of Covid-19, but 
follow-up monitoring after discharge for 
long-term effects (long hauler Covid-19) is 
needed. Of the patients recovering from 
COVID-19, around 87.4% said that there 
was at least one persistent symptom, 
especially fatigue and dyspnea. The most 
common symptoms are fatigue, shortness of 
breath, cough, joint pain, and chest pain.4 
While long-term symptoms include 
difficulty thinking and concentration, 
depression, muscle aches, headaches, chest 
pain, intermittent fever, tachycardia.3, 5 
The phenomenon of Covid-19 long hauler 
patients at Tugurejo Hospital who have 
severe symptoms is treated in the Covid-19 
ICU room, but if the results of PCR swabs 
that have been carried out 2 times in a row 
are negative and require critical care 19. 
This patient who has tested negative for 
Covid-19 still feels symptoms of dyspnea, 
fatigue, joint pain, reduced muscle function, 
impaired ability to perform daily activities, 
and mental health problems such as post-
traumatic stress disorder, anxiety, and 
depression. The number of long hauler 
cases covid-19 in December 2020-February 
2021 was 30 patients. There were 15 
patients given oxygen therapy through 
HFNC, 5 patients received oxygen therapy 
through mechanical ventilation, 7 patients 
received oxygen through a non-rebreathing 
mask, 3 patients received oxygen therapy 
through a nasal cannula and 1 patient 
experienced worsening conditions from 
HFNC oxygen therapy to a mechanic 
ventilator. The duration of using HFNC and 
the length of stay of these patients varied 
between 5-14 days. 
The main life-threatening problem for 
Covid-19 long hauler patients is a problem 
attacking the respiratory system and some 
patients in the course of the disease will 
develop insufficient refractory hypoxemic 
breathing which requires mechanical 
ventilation. Currently, the non-invasive 
method of giving high concentration oxygen 
through HFNC is a modality in Long hauler 
Covid-19 patients, especially those who 
experience moderate and severe ARDS 
failure.6, 7  Delaying or preventing 
mechanical ventilation procedures can 
reduce the need for a ventilator.8 Nasal 
high-flow oxygen therapy (HFNC) allows 
the delivery of warm and humidified gases 
at a high flow rate and the appropriate 
fraction of inspired oxygen (FiO2), is 
currently frequently used in patients with 
hypoxemic acute respiratory failure 
(HARF).9 
A 2020 study showed that 28 patients with 
severe COVID-19 symptoms, 67.8% of 
patients with HFNC improved, 32.2% of 
patients failed using HFNC and needed NIV, 
17.8% required intubation.10 HFNC also 
plays an important role in correcting 
hypoxemia in about two-thirds of patients 
with Covid-19. From previous studies, there 
has been no specific study for Covid-19 long 
hauler patients. This case study aims to 
determine the effect of oxygen therapy 
through HFNC on specific patient outcomes, 
namely improving breathing patterns, 
lowering respiratory frequency, increasing 
oxygen saturation and increasing blood 
oxygen pressure (PaO2) of Covid-19 long 
hauler patients in critical care rooms. 
METHODS 
This study is a case study of nursing care 
using pre and post test conducted on 2 
respondents with a descriptive approach 
method. The variable of this study was 
HFNC oxygen therapy on the respiratory 
function of Covid-19 long hauler patients. 
This study was conducted in the critical care 
room of Tugurejo Hospital on February 4-
February 15, 2021. 
Covid-19 patients whose PCR results were 2 
times negative and/or patients who had a 
history of Covid-19 in the past were the 
population of this study. The subjects of this 
study consisted of 2 patients obtained by 
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purposive sampling. Sampling according to 
the inclusion criteria, namely long hauler 
Covid-19 patients with comorbid Diabetes 
Mellitus who had severe breathing 
problems, the patient was conscious and 
able to communicate. Exclusion criteria of 
the patient were no longer able to continue 
the study because of severe breathlessness, 
worsening of the condition and requiring 
mechanical ventilation. 
The instruments in this case study were the 
HFNC machine, bed side monitor, oximetry, 
and blood gas analysis results. Data 
collection procedures: a) Determine the 
patient according to the criteria. b) Provide 
informed consent to prospective 
respondents. c) After the prospective 
respondent agrees to become a respondent, 
the researcher contracts the time to do the 
research. d) Record the breath pattern, 
measure the respiratory frequency, oxygen 
saturation, and record the measurement 
results in the respiratory function status 
column before being given intervention. d) 
Researchers provide intervention to 
respondents in the form of HFNC oxygen 
therapy with a flow of 60 L/minute and 90% 
FiO2. e) Every day the patient is re-
measured the respiratory function status 
until day 5. f) Record the measurement 
results in the respiratory function status 
column after the intervention. g) Give HFNC 
oxygen therapy in accordance with the 
development of the patient's condition 
every day. 
RESULTS 
The subjects of this case study were 2 
people, consisting of male and female 
patients. Patient characteristics in both 
cases can be seen in Table 1 and the 
assessment results in both cases are shown 
in Table 2. 
First case; A 52 years old male was 
admitted to the critical care room with 
complaints of severe shortness of breath, 
cough, swallowing pain, weakness, lack of 
appetite, desaturation and compos mentis 
awareness. The patient had a history of 
diabetes mellitus with his blood sugar 
currently under control. The patient did not 
have fever, blood pressure and pulse rate 
were within normal limits. The results of 
laboratory tests of blood gas analysis 
obtained data on oxygen levels in the blood 
(PO2) 45 mmHg, the P/F ratio of the results 
was 50 (severe ARDS), the D-dimer test was 
2030 ug/L, the blood sugar when the results 
were 146 g/dl and X-rays. the result 
typically viral pneumonia. Physical 
examination obtained data on complaints of 
severe shortness of breath, respiratory rate 
31 times per minute, 88% oxygen 
saturation, blood pressure 126/92 mmHg, 
pulse 100 times per minute and 
temperature 36.5 ° C. Diet Low in sugar and 
carbohydrates. The patient experienced 
major nursing problems as ineffective 
breathing patterns and impaired gas 
exchange. Patients received oxygen therapy 
through HFNC flow of 60 liters per minute 
and a concentration of 90%, ROX 3.19, 
heparin syringe pump 10,000 IU per 24 
hours, meropenem injection therapy 500 
mg per 8 hours, Novorapid 0-0-10 IU (SC) 
and bricasma inhalation therapy combined 
with heparin 25,000 IU every 6 hours. 
Acetyl cysteine oral therapy 3 times per day. 
The patient received RL/Tutofusin infusion 
therapy 30 drops per minute. 
Second case; A 58 years old woman was 
admitted to the critical care room with 
complaints of severe shortness of breath, 
cough, swallowing pain, weakness, lack of 
appetite, desaturation, restlessness and 
compos mentis awareness. The patient had 
a history of diabetes mellitus with his blood 
sugar currently under control. The patient 
did not have fever, blood pressure and pulse 
rate were within normal limits. The results 
of laboratory examination of blood gas 
analysis obtained data on oxygen levels in 
the blood (PO2) 45 mmHg, the P/F ratio was 
50 (severe ARDS), ROX 2.95, the D-dimer 
examination was 2100 ug/L, blood sugar at 
170 gr/dl and Chest X-ray results typically 
viral bilateral pneumonia. Physical 
examination obtained data on complaints of 
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severe shortness of breath, respiratory rate 
of 35 times per minute, oxygen saturation of 
93%, blood pressure of 126/85 mmHg, 
pulse 80 times per minute and temperature 
of 36.3 ° C. Diet low in sugar and 
carbohydrates. The patient experienced 
major nursing problems as ineffective 
breathing patterns and impaired gas 
exchange. Patients received oxygen therapy 
through HFNC flow 60 liters per minute and 
a concentration of 90%, heparin syringe 
pump 10,000 iu per 24 hours, meropenem 
injection therapy 1 gram per 8 hours, 
Novorapid 14 IU per 8 hours (SC) and 
bricasma inhalation therapy combined with 
heparin 25,000 IU every 6 hours. Acetyl 
cysteine oral therapy 1 tablet per 8 hours. 
The patient received infusion therapy of 
RL/Tutofusin 20 drops per minute. 
The nursing diagnoses that occurred in 
these 2 patients were ineffective breathing 
patterns and impaired gas exchange. 
Nursing problems that occur in 
physiological subcategory disorders are gas 
exchange disorders associated with 
increased airway resistance and decreased 
pulmonary complaints, hyperthermia 
associated with lung virus infections.11, 12 
Nursing intervention given is to measure 
the frequency of breathing, increase oxygen 
saturation and increase oxygen pressure in 
the blood (PaO2). Then the patient is given 
HFNC oxygen therapy according to the 
patient's needs. 
Implementation of nursing measures: the 
patient's respiratory status is measured and 
the results of laboratory tests. Then the 
patient was given HFNC oxygen therapy 
with initial parameters of flow 60 and FiO2 
90% for 5 days. Evaluations are carried out 
every day to determine the progress of the 
patient's condition so that oxygen 
administration is tailored to the patient's 
needs. 
Table 2 shows that 2 patients after being 
given HFNC oxygen therapy for 5 days 
experienced an improvement in the 
respiratory frequency of patient 1, namely 
from 26 times/ minute to 22 times/minute 
and patient 2 the frequency of breathing on 
the first day 35 times/ minute after day 5 to 
19 times/minute. The breathing patterns of 
patients 1 and 2 on days 1 and 5 also 
experienced a change from shortness of 
breath to not shortness of breath. The 
oxygen saturation in patient 1 on the first 
day was 94% after day 5 to 97% and patient 
2 on the first day 92% after day 5 to 99%. 
Laboratory results PO2 of patient 1 first day 
45 after day 5 to 99 and patient 2 on day 45 
after day 5 to 164. Blood pH was within 
normal limits. The ROX index on day 5 in 
patient 1 became 8.82 and 10.42 in patient 
2. The HFNC oxygen parameter decreased 
according to the development of the 
patient's condition each day. HFNC oxygen 
flow and FiO2 in patients 1 and 2 on the first 
day were 60 L/min and 90% after day 5 the 
HFNC flow and FiO2 oxygen in patient 1 
were 40 L/min and 50%, the second 





Indicators  Case 1 Case 2 
Gender Male Female 
Age 52 years old 58 years old 
Comorbid Diabetes Mellitus Diabetes Mellitus 
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Table 2 
Hemodynamic parameters and laboratory test results 
 Case 1 Case 2 
Day 1 2 3 4 5 1 2 3 4 5 
Parameter   
HFNC Flow 60 55 55 50 40 60 60 50 40 30 
FiO2 90 80 70 60 50 90 90 80 60 50 
pH 7.45 7.47 7.45 7.45 7.46 7.46 7.46 7.45 7.46 7.47 
PO2 45 46 51 67 99 45 51 71 80 164 
P/F ratio 50 57.5 72.8 111.6 198 50 56 88 133 328 
Breathing pattern 
(dyspnea) 
+ + - - - + + - - - 
RR 26 26 21 26 22 35 26 24 22 19 
SpO2 94 94 94 95 97 92 95 97 98 99 
ROX index 4.02 4.52 6.39 6.09 8.82 2.92 4.06 5.05 7.42 10.42 
 
DISCUSSION 
The results of this case study indicate that 
after maximal administration of HFNC 
oxygen at the start of each day of 
administration it can be reduced according 
to the patient's oxygen requirements. After 
giving HFNC oxygen therapy to this Covid-
19 long hauler patient also showed a 
decrease in breathing frequency, changes in 
breathing patterns from shortness to 
shortness of breath, increased oxygen 
saturation, and an increase in the ROX 
index, an increase in PO2 and blood pH 
within normal limits. 
Severe, progressive shortness of breath and 
complications of ARDS often experience a 
happy hypoxic condition characterized by 
compos mentis awareness, shortness of 
breath, desaturation and severe hypoxemia 
are symptoms that often occur in Long 
Hauler Covid-19 patients.13 This is in 
accordance with the conditions that 
occurred in this case study. The patient 
characteristics in this case study were 
diabetes mellitus patients. The 
phenomenon of Covid-19 and long hauler 
covid-19 patients requires intensive care 
and occurs in patients who have a history of 
diabetes mellitus because they have a very 
severe inflammatory response.14 The 
special surface glycoproteins in ACE2 are 
the entry port for the Covid-19 virus. ACE2 
is abundant in the alveolar type II cells of the 
lungs. If the amount of ACE2 in excess can 
worsen the patient's condition. This can 
lead to ARDS, damage to the liver, heart, 
kidneys, and even death. Patients with 
comorbid diabetes mellitus tend to be twice 
as likely to suffer from severe symptoms of 
COVID-19 and two times more likely to die 
from these symptoms.15 
The principle of oxygen therapy with HFNC 
is based on a device capable of providing a 
high flow of oxygen demand through a 
warm and moist nasal cannula. This cannula 
can provide flows of up to 60 L/minute at a 
temperature of 31-37℃ with an absolute 
humidity of 44 mg H2O/L; FiO2 varies 
between 21-100%. The advantages of HFNC 
include clearing the pharyngeal dead space, 
reducing respiratory effort, the effect of 
PEEP (Positive End-Expiratory Pressure), 
providing a constant fraction of inspired 
oxygen, patient comfort and improved 
muco-ciliary clearance. HFNC is also known 
to provide a low PEEP, which can improve 
the condition of patients with mild-to-
moderate respiratory failure. In addition, by 
providing a warm, humidified gas, HFNC 
reduces the metabolic effort required to 
condition the air. HFNC is more tolerable 
than other ventilatory supports and reduces 
the incidence of intubation thus providing a 
good clinical prognosis in patients with 
acute respiratory failure.16 
HFNC was also studied to have an important 
role in correcting hypoxemia in about two-
thirds of patients with COVID-19 with 
severe hypoxemic respiratory failure who 
were unable to achieve SatO2 ≥ 92% with 
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standard oxygen therapy. A study showed 
28 patients with severe COVID-19 
symptoms, about 67.8% of patients with 
HFNC improved and could be transferred to 
a normal room, 32.2% of patients failed 
using HFNC and needed NIV, 17.8% 
required intubation.10 This improvement in 
oxygenation is related to air flow that is in 
accordance with ventilation requirements, 
high and stable FiO2, cleaning of the upper 
airways, the presence of positive pressure 
(PEEP), and providing warm and humid air. 
Patients with a PaO2/FiO2 ≤ 100 mmHg are 
at risk of failing HFNC therapy.10 
This case study was the initial 
administration of HFNC oxygen therapy 
with a flow of 60 L/min and a FiO2 of 90%. 
Every day the patient's condition shows an 
improvement in the status of respiratory 
function so that the HFNC oxygen therapy is 
gradually reduced. Until day 5, the HFNC 
oxygen therapy given was a flow of 40 
L/min and FiO2 of 50% in patient 1, flow of 
30 L/min and FiO2 of 50% in patient 2. A 
study also showed about 61.9% (65 
subjects) patients show improved 
oxygenation and can be removed from 
HFNC.17 Assessment of the ROX index at 6 
hours of HFNC administration provides a 
predictive value for the patient's 
oxygenation status and a predictor of the 
success of HFNC therapy.18 An ROX index of 
more than 5.55 at 6 hours of HFNC 
administration was associated with HFNC 
success (sensitivity 61.1% specificity 
84.6%). This assessment can help the 
clinician to prevent a late intubation that 
will lead to a poor prognosis. An ROX index 
below 2.85 at 2 hours, below3.47 at 6 hours 
and below 3.85 at 12 hours is a predictor of 
failure of HFNC therapy.19 In this case study, 
the ROX index results after administration 
of HFNC oxygen therapy on day 5 were 8.82 
in patients and 10.42 in patients 2. The 
effectiveness and comfort of HFNC needed 
to be evaluated every 2 and 48 hours. 
Thrombocytopenia, increased IL-6 upon 
initiation of HFNC, ROX index <5.31 in the 
first 4 hours of HFNC therapy were 
independent predictors of failure of HFNC 
therapy. Prolonged use of HFNC is not 
associated with a poor prognosis. APACHE 
II and PSI scores can be used to determine 
when intubation is needed so that it is not 
late.20 
CONCLUSION 
Nasal high-flow oxygen therapy is proven to 
be an additional option and alternative 
method of respiratory support in Long 
Hauler Covid-19 patients. This is evidenced 
by an improvement in the respiratory 
function of Covid-19 long hauler patients in 
critical rooms after being given HFNC 
oxygen therapy. This case report shows the 
results of improvement in respiratory 
function while being treated in the critical 
care room receiving oxygen therapy 
through HFNC. 
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